SEPN Stock Analysis: Buy, Sell, or Hold?
SEPN - Septerna, Inc. Common Stock
$35.95
1.92 (5.64%)
▲
5d:
+15.41%
30d:
+45.25%
90d:
+43.0%
HOLD
MODERATE Confidence
Analysis Updated: Jun 12, 2026 12:00 AM ET
Earnings: May 21, 2026
0d
Get Alerted When SEPN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: SEPN is 12.7% above its trading range ($31.89). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: SEPN is 12.7% above its trading range ($31.89). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
In-depth Analysis How we analyze
Valuation Analysis: SEPN is currently trading at $35.95, which is considered extended relative to its 30-day fair value range of $25.79 to $31.89.
Technical Outlook: Technically, SEPN is in a uptrend. The price is approaching resistance at $36.26. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 5.6% recently.
Market Sentiment: SEPN has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $45.78 (+27.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, SEPN is in a uptrend. The price is approaching resistance at $36.26. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 5.6% recently.
Market Sentiment: SEPN has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $45.78 (+27.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$25.79 -
$31.89
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BEARISH: Price significantly overextended (+12.7% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+5.6%)
- BULLISH: Trading 27.3% below Wall St target ($45.78)
Trading Range Analysis
30-Day Trading Range
$25.79 -
$31.89
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$27.08
Resistance Level
$36.26
Current Trend
Uptrend
Technical data as of
Jun 12, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-13.52
Wall Street Target
$45.78
(+27.3%)
Revenue Growth (YoY)
12011.0%
Profit Margin
-49.9%
Share & Embed Analysis
Last updated: June 15, 2026 7:54 AM ET
Data refreshes hourly during market hours. Next update: 8:54 AM
Data refreshes hourly during market hours. Next update: 8:54 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SEPN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
Elizabeth Bhatt
SELL
4000 shares
2026-04-15
Samira Shaikhly
SELL
70453 shares
2026-03-02
Elizabeth Bhatt
SELL
4000 shares
2026-02-18
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1029 | 63 BUY |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$84 | 48 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 51 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$297 | 52 HOLD |
|
BEAM
Beam Therapeutics Inc |
STRONG BUY
17 analysts |
$51 | 55 HOLD |
